Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FINASTERIDE vs ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Finasteride is a competitive 5-alpha-reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (DHT), thereby reducing DHT levels in serum and prostate tissue.
Acetaminophen: inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis; analgesic and antipyretic. Caffeine: adenosine receptor antagonist; enhances analgesic effect. Dihydrocodeine: mu-opioid receptor agonist; produces analgesia via central opioid receptors.
Benign prostatic hyperplasia (BPH),Male pattern baldness (androgenetic alopecia)
Management of mild to moderate pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate,Off-label: acute pain, chronic pain
1 mg orally once daily for androgenetic alopecia; 5 mg orally once daily for benign prostatic hyperplasia.
1-2 tablets (each containing acetaminophen 300 mg, caffeine 30 mg, dihydrocodeine bitartrate 20 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Terminal elimination half-life is approximately 6-8 hours (range 4-12 hours) in young adults; prolonged to ~8 hours in elderly due to reduced clearance; clinical effect on DHT suppression persists for 24 hours post-dose.
Acetaminophen: 2-3 hours (normal), prolonged in hepatic impairment. Caffeine: 3-6 hours (adults), prolonged in liver disease or with oral contraceptives. Dihydrocodeine: 3.5-6 hours (terminal). Clinical context: q6h dosing interval appropriate; accumulation risk in renal/hepatic impairment.
Metabolized primarily via CYP3A4 in the liver; two inactive metabolites (t-butyl side chain oxidation and glucuronide conjugate).
Acetaminophen: primarily hepatic via glucuronidation and sulfation; minor CYP2E1, CYP1A2, CYP3A4. Caffeine: hepatic via CYP1A2. Dihydrocodeine: O-demethylation to dihydromorphine via CYP2D6; also via CYP3A4.
Renal (39% as metabolites, <0.1% as unchanged drug); fecal (57% as metabolites); biliary elimination contributes to fecal route.
Acetaminophen: renal excretion of metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate 8%), <5% unchanged. Caffeine: renal excretion of metabolites (1-methyluric acid, 1-methylxanthine, etc.), <2% unchanged. Dihydrocodeine: renal excretion of metabolites (dihydrocodeine-6-glucuronide, nordihydrocodeine, dihydromorphine), ~20% unchanged. Overall, predominantly renal (≥85%), minor biliary/fecal.
Approximately 93% bound to plasma proteins (primarily albumin and to a lesser extent alpha-1-acid glycoprotein).
Acetaminophen: 10-25% (albumin). Caffeine: 25-36% (albumin). Dihydrocodeine: ~20-30% (albumin and α1-acid glycoprotein).
Volume of distribution = 76 L (approximately 1.0-1.1 L/kg), indicating extensive tissue distribution; crosses blood-brain barrier and partitions into seminal fluid.
Acetaminophen: 0.7-1.0 L/kg. Caffeine: 0.5-0.8 L/kg. Dihydrocodeine: 1.0-1.5 L/kg. Clinical meaning: moderate distribution, potential for central nervous system penetration.
Oral bioavailability is approximately 63% (range 50-80%) due to incomplete absorption and first-pass metabolism; food does not significantly affect bioavailability.
Acetaminophen: oral 75-85%. Caffeine: oral ~100%. Dihydrocodeine: oral ~20-30% (first-pass metabolism; extended-release formulations have altered bioavailability).
No dose adjustment required for any level of renal impairment including end-stage renal disease.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-30 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; avoid in severe impairment due to dihydrocodeine accumulation.
No formal studies in hepatic impairment. Caution advised; use not recommended in severe hepatic impairment due to potential accumulation. No specific Child-Pugh based dose recommendations.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval to every 8 hours; Child-Pugh C: avoid use due to acetaminophen hepatotoxicity and dihydrocodeine accumulation.
Not indicated in pediatric patients. Safety and efficacy not established. Avoid use in children.
Not recommended for children under 12 years due to dihydrocodeine risks; for adolescents 12-18 years: 1 tablet orally every 4-6 hours as needed, maximum 4 tablets per day (weight-based dosing not established).
No age-related dose adjustment necessary. Monitor for adverse effects (e.g., sexual dysfunction, mood changes) due to potential increased sensitivity.
Initiate with 1 tablet orally every 6 hours; caution due to increased sensitivity to opioids and hepatotoxicity from acetaminophen; maximum 4 tablets per day; monitor renal and hepatic function.
No FDA black box warning.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen can cause fatal hepatotoxicity; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Risk of high-grade prostate cancer (decreased PSA levels may mask detection),Sexual adverse effects (e.g., decreased libido, erectile dysfunction, ejaculatory disorder) may persist after discontinuation,Increased risk of mood disturbances including depression and suicidal ideation,Not indicated for use in women or children; avoid handling crushed tablets during pregnancy due to risk to male fetus
Addiction, abuse, and misuse; respiratory depression; acetaminophen hepatotoxicity; drug interaction with benzodiazepines and CNS depressants; neonatal opioid withdrawal syndrome; risk of serotonin syndrome; severe hypotension; adrenal insufficiency; use in patients with head injury or increased intracranial pressure; seizures; avoid in patients with severe hepatic impairment.
Pregnancy (category X; risk of hypospadias in male fetuses),Known hypersensitivity to finasteride or any component of the formulation
Hypersensitivity to any component; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; suspected surgical abdomen; concomitant use with MAOIs or within 14 days; severe hepatic impairment.
No significant food interactions reported; finasteride may be taken with or without food. Avoid excessive alcohol consumption as it may worsen BPH symptoms or liver function.
Avoid alcohol; may increase risk of hepatotoxicity and CNS depression. High-fat meals may delay absorption but do not significantly affect overall exposure. Caffeine-containing foods and beverages may increase stimulant effects.
Contraindicated in pregnancy. Finasteride inhibits conversion of testosterone to dihydrotestosterone, which is critical for male fetal external genitalia development. Risk of hypospadias and other urogenital malformations if exposed in utero, particularly during first trimester. Pregnancy category X.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity. Caffeine: High doses (>200 mg/day) associated with increased miscarriage risk; limited data on malformations. Dihydrocodeine: Opioid; first trimester: increased risk of neural tube defects (OR 2.0-2.5); third trimester: risk of neonatal opioid withdrawal syndrome (NOWS). Overall, combination product should be used only if benefit outweighs risks.
Not recommended. Finasteride is excreted in human milk; M/P ratio not reported. Risk to nursing infant unknown, but potential for adverse effects on male infant genitalia. Use contraindicated during breastfeeding.
Acetaminophen: Excreted in breast milk (M/P ratio ~0.9); safe at therapeutic doses. Caffeine: Excreted (M/P ~0.5-0.8); moderate intake (<300 mg/day) generally safe. Dihydrocodeine: Excreted in low levels; however, interindividual variability in metabolism (CYP2D6) may lead to higher morphine concentrations in some infants; risk of neonatal respiratory depression. M/P ratio not well established for dihydrocodeine. Use with caution, monitor infant for sedation and feeding difficulties.
No dose adjustments applicable as finasteride is contraindicated in pregnancy. No pharmacokinetic studies in pregnant women due to ethical concerns.
No specific dose adjustments for pregnancy due to lack of pharmacokinetic studies for this combination. However, note: Increased clearance of acetaminophen in pregnancy may require higher doses for analgesia but remains within standard limits. Caffeine clearance decreases in third trimester; consider reducing intake to <200 mg/day. Dihydrocodeine: Increased volume of distribution and clearance in pregnancy; dose may need titration but no established guidelines. Use lowest effective dose for shortest duration.
Finasteride inhibits 5α-reductase type II, reducing conversion of testosterone to DHT. Onset of effect in benign prostatic hyperplasia (BPH) requires 6-12 months; for androgenetic alopecia, 3-6 months. Serum PSA levels decrease by approximately 50% after 6 months; multiply PSA by 2 when interpreting. Avoid handling crushed or broken tablets if pregnant or planning to become pregnant due to risk of fetal genital abnormalities. Use with caution in hepatic impairment; contraindicated in women of childbearing potential, children, and patients with hypersensitivity to 5α-reductase inhibitors.
Dihydrocodeine is a prodrug requiring CYP2D6 metabolism to active metabolites; poor metabolizers may have reduced efficacy while ultrarapid metabolizers risk toxicity. Caffeine potentiates analgesia and may cause insomnia with evening use. Do not exceed 8 tablets per 24 hours due to acetaminophen hepatotoxicity risk. Use with caution in elderly and patients with renal impairment.
Take finasteride exactly as prescribed, once daily with or without food.,It may take 3-6 months for hair regrowth or improvement in urinary symptoms; continue therapy as directed even if no immediate benefit is noted.,Report any breast tenderness, enlargement, or lumps; also report any new onset of sexual dysfunction (e.g., decreased libido, erectile dysfunction, ejaculation disorder).,Do not donate blood while taking finasteride and for at least 1 month after stopping, to prevent exposure to a pregnant female.,Women who are pregnant or may become pregnant should not handle crushed or broken tablets due to risk of harm to male fetus.,Serum PSA levels will decrease; inform your healthcare provider that you take finasteride before any PSA test.,Store at room temperature (20-25°C) in a dry place, away from light and moisture.
Take with food if stomach upset occurs.,Avoid alcohol and products containing acetaminophen to prevent liver damage.,Do not exceed 8 tablets in 24 hours.,May cause drowsiness; avoid driving or operating machinery until you know how this medication affects you.,If you have a history of drug dependence, use with caution as dihydrocodeine can be habit-forming.
"Finasteride, a 5α-reductase inhibitor used for benign prostatic hyperplasia, may inhibit cytochrome P450 3A4 (CYP3A4) isoenzymes. Cyclosporine is primarily metabolized by CYP3A4. Coadministration can lead to reduced cyclosporine clearance, elevated blood concentrations, and increased risk of nephrotoxicity, hypertension, and neurotoxicity."
"Finasteride, a 5α-reductase inhibitor used for benign prostatic hyperplasia, may weakly inhibit CYP3A4, the primary enzyme responsible for sildenafil metabolism. This can lead to a modest reduction in sildenafil clearance, increasing systemic exposure and potentially enhancing both therapeutic effects and adverse events such as headache, flushing, dyspepsia, and hypotension. Clinically, this interaction is generally mild but may require dose adjustment in patients predisposed to sildenafil side effects."
"Finasteride, a 5α-reductase inhibitor, may inhibit CYP3A4-mediated metabolism of netupitant, a neurokinin-1 receptor antagonist primarily metabolized by CYP3A4. This can lead to increased netupitant plasma concentrations, potentially enhancing its adverse effects such as headache, fatigue, or dizziness. Clinically, the combination may require dose adjustment or close monitoring for netupitant toxicity."
"The combination of chlordiazepoxide, a benzodiazepine that enhances GABAergic inhibition, and dihydrocodeine, an opioid agonist primarily at mu-receptors, results in additive central nervous system (CNS) depression. This synergy increases the risk of profound sedation, respiratory depression, coma, and death, particularly in vulnerable populations such as the elderly or those with pre-existing respiratory compromise. Concurrent use also elevates the potential for hypotension and psychomotor impairment, leading to falls or accidents."
"Reserpine depletes catecholamines in the central nervous system and peripheral adrenergic neurons, leading to reduced sympathetic outflow. Dihydrocodeine, an opioid agonist, can cause further central nervous system depression and hypotension. When combined, there is an additive risk of excessive hypotension, bradycardia, and profound sedation, potentially leading to falls or respiratory depression."
"Dihydrocodeine, an opioid analgesic, undergoes O-demethylation primarily via CYP2D6 to form dihydromorphine, which contributes to its analgesic effects. Clemastine, a first-generation antihistamine, is metabolized mainly by CYP2D6 as well. When co-administered, clemastine competitively inhibits CYP2D6, reducing the clearance of dihydrocodeine and decreasing the formation of the active metabolite dihydromorphine. This can lead to diminished analgesic efficacy and potentially increased levels of parent dihydrocodeine, heightening the risk of opioid-related adverse effects such as respiratory depression, sedation, and constipation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FINASTERIDE vs ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, answered by our medical review team.
FINASTERIDE is a 5-alpha Reductase Inhibitor that works by Finasteride is a competitive 5-alpha-reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (DHT), thereby reducing DHT levels in serum and prostate tissue.. ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is a Opioid Agonist that works by Acetaminophen: inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis; analgesic and antipyretic. Caffeine: adenosine receptor antagonist; enhances analgesic effect. Dihydrocodeine: mu-opioid receptor agonist; produces analgesia via central opioid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FINASTERIDE and ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FINASTERIDE is: 1 mg orally once daily for androgenetic alopecia; 5 mg orally once daily for benign prostatic hyperplasia.. The standard adult dose of ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is: 1-2 tablets (each containing acetaminophen 300 mg, caffeine 30 mg, dihydrocodeine bitartrate 20 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FINASTERIDE and ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FINASTERIDE is classified as Category D/X. Contraindicated in pregnancy. Finasteride inhibits conversion of testosterone to dihydrotestosterone, which is critical for male fetal external genitalia development. Risk of hypos. ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is classified as Category D/X. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity. Caffeine: High doses (>200 mg/day) associated with increased miscarriage risk; limited data . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.